Chronic Lymphocytic Leukemia
We recommend
OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?
Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…
Articles on this topic
Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
In the context of the significant advancements in the field of immunotherapy and evidence of…
Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype
A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic…
New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?
The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly…
Journal articles Evolution of chronic lymphocytic leukemia treatment over the past 25 years
Nárůst poznatků o buněčné povaze, patogenezi a genetických změnách chronické lymfocytární leukemie...
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Chronic lymphocytic leukaemia – contemporary application of modern prognostic and predictive markers in diagnostics
- Venetoclax Treatment Strategies in Patients with CLL
- Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
- Evolution of chronic lymphocytic leukemia treatment over the past 25 years
- Current Treatment Options for Refractory/Relapsed CLL
- Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
Journal on this topic
Related topic